Sirna Therapeutics Announces Exercise of Over-Allotment Option By Underwriters
30 May 2006 - 10:03PM
PR Newswire (US)
SAN FRANCISCO, May 30 /PRNewswire-FirstCall/ -- Sirna Therapeutics,
Inc. (NASDAQ:RNAI) announced today the exercise in full by the
underwriters of an over-allotment option to purchase 1,350,000
shares of common stock in connection with its follow-on stock
offering that priced on May 23, 2006. Including the over-allotment
shares, the offering will total 10,350,000 shares at a public
offering price of $5.00 per share, resulting in an aggregate public
offering price of approximately $52 million and estimated net
proceeds to the company of approximately $47 million. UBS
Investment Bank and J.P. Morgan Securities Inc. are acting as joint
bookrunning managers for the offering. Co-managers for the offering
are CIBC World Markets, Leerink Swann & Company and Brean
Murray, Carret & Co. A copy of the prospectus supplement
relating to the offering may be obtained by contacting UBS
Investment Bank, Prospectus Department, 299 Park Avenue, New York,
New York 10171 (212-821-3000), or J.P. Morgan Securities Inc.,
Prospectus Department, 4 Chase Metrotech Center, CS Level,
Brooklyn, New York 11245 (718-242-8002). This communication shall
not constitute an offer to sell or the solicitation of an offer to
buy, nor shall there be any sale of these securities in any
jurisdiction in which the offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction. About Sirna Therapeutics
Sirna Therapeutics is a clinical-stage biotechnology company
developing RNAi-based therapies for serious diseases and
conditions, including age-related macular degeneration, hepatitis B
and C, dermatology, asthma, Huntington's disease, diabetes, and
respiratory syncytial virus. Safe Harbor Statement Statements in
this press release which are not strictly historical, including
with respect to Sirna's proposed public offering, are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. You should consider the risk
factors identified in the prospectus supplement and the
accompanying prospectus, and in Sirna's Securities and Exchange
Commission filings, including its Forms 10-K and 10-Q and in other
SEC filings. Sirna undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
Contacts: Greg Weaver, SVP and Chief Financial Officer, Sirna
Therapeutics, Inc., 415-512-7200 Rebecca Galler Robison, Senior
Director, Corporate Strategy, Sirna Therapeutics, Inc.,
303-449-6500 DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Greg
Weaver, SVP and Chief Financial Officer, +1-415-512-7200, or
Rebecca Galler Robison, Senior Director, Corporate Strategy,
+1-303-449-6500, both of Sirna Therapeutics, Inc. Web site:
http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Sep 2023 to Sep 2024